Figure 3.
Figure 3. Multilineage engraftment of NOD/SCID mice. (A) Analysis of myelopoiesis, B lymphopoiesis, and megakaryocytopoiesis in the BM of the NOD/SCID mice that received transplants of either normal G-CSF-mobilized PB (□;n = 3) or IM PB (▪;n = 3) CD34+ cells. Overall distribution of myeloid (CD33+) lineages, B-lymphoid (CD19+) lineages, progenitor cells (CD34+), and megakaryocytes (CD41+) among human cells (CD45+). Values are shown as the mean ± SD. (B) Representative flow cytometric analysis of BM from mice that received transplants of PB CD34+ cells from a G-CSF-mobilized volunteer (top row) or a patient with IM (bottom row). BM cells were analyzed by flow cytometry at 9 to 15 weeks after transplantation.

Multilineage engraftment of NOD/SCID mice. (A) Analysis of myelopoiesis, B lymphopoiesis, and megakaryocytopoiesis in the BM of the NOD/SCID mice that received transplants of either normal G-CSF-mobilized PB (□;n = 3) or IM PB (▪;n = 3) CD34+ cells. Overall distribution of myeloid (CD33+) lineages, B-lymphoid (CD19+) lineages, progenitor cells (CD34+), and megakaryocytes (CD41+) among human cells (CD45+). Values are shown as the mean ± SD. (B) Representative flow cytometric analysis of BM from mice that received transplants of PB CD34+ cells from a G-CSF-mobilized volunteer (top row) or a patient with IM (bottom row). BM cells were analyzed by flow cytometry at 9 to 15 weeks after transplantation.

Close Modal

or Create an Account

Close Modal
Close Modal